281 related articles for article (PubMed ID: 21940504)
1. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
Gahramanov S; Muldoon LL; Li X; Neuwelt EA
Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
[TBL] [Abstract][Full Text] [Related]
2. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.
Paulson ES; Schmainda KM
Radiology; 2008 Nov; 249(2):601-13. PubMed ID: 18780827
[TBL] [Abstract][Full Text] [Related]
4. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
5. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.
Varallyay CG; Muldoon LL; Gahramanov S; Wu YJ; Goodman JA; Li X; Pike MM; Neuwelt EA
J Cereb Blood Flow Metab; 2009 Apr; 29(4):853-60. PubMed ID: 19142191
[TBL] [Abstract][Full Text] [Related]
6. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.
Hu LS; Kelm Z; Korfiatis P; Dueck AC; Elrod C; Ellingson BM; Kaufmann TJ; Eschbacher JM; Karis JP; Smith K; Nakaji P; Brinkman D; Pafundi D; Baxter LC; Erickson BJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2242-9. PubMed ID: 26359151
[TBL] [Abstract][Full Text] [Related]
7. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
8. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.
Muldoon LL; Gahramanov S; Li X; Marshall DJ; Kraemer DF; Neuwelt EA
Neuro Oncol; 2011 Jan; 13(1):51-60. PubMed ID: 21123368
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
10. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
Thompson EM; Guillaume DJ; Dósa E; Li X; Nazemi KJ; Gahramanov S; Hamilton BE; Neuwelt EA
J Neurooncol; 2012 Aug; 109(1):105-14. PubMed ID: 22528798
[TBL] [Abstract][Full Text] [Related]
11. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
[TBL] [Abstract][Full Text] [Related]
12. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Yang S; Babb JS; Knopp EA; Golfinos JG; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2004 May; 25(5):746-55. PubMed ID: 15140713
[TBL] [Abstract][Full Text] [Related]
14. Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.
Stokes AM; Semmineh NB; Nespodzany A; Bell LC; Quarles CC
Magn Reson Med; 2020 Jan; 83(1):109-123. PubMed ID: 31400035
[TBL] [Abstract][Full Text] [Related]
15. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas.
Law M; Young R; Babb J; Pollack E; Johnson G
AJNR Am J Neuroradiol; 2007 Apr; 28(4):761-6. PubMed ID: 17416835
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
[TBL] [Abstract][Full Text] [Related]
17. Comparison of first-pass and second-bolus dynamic susceptibility perfusion MRI in brain tumors.
Spampinato MV; Wooten C; Dorlon M; Besenski N; Rumboldt Z
Neuroradiology; 2006 Dec; 48(12):867-74. PubMed ID: 17013587
[TBL] [Abstract][Full Text] [Related]
18. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.
Cebeci H; Aydin O; Ozturk-Isik E; Gumus C; Inecikli F; Bekar A; Kocaeli H; Hakyemez B
Eur J Radiol; 2014 Oct; 83(10):1914-9. PubMed ID: 25087109
[TBL] [Abstract][Full Text] [Related]
19. The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard.
Boxerman JL; Prah DE; Paulson ES; Machan JT; Bedekar D; Schmainda KM
AJNR Am J Neuroradiol; 2012 Jun; 33(6):1081-7. PubMed ID: 22322605
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
